Leticia Tarilonte joined Brainstorm in November 2023 and serves as Vice President of Global Clinical Operations.

Leticia has over 25 years of industry experience managing research projects and clinical studies in various roles. She started her career at Biogen, working collaboratively in an integrated monoclonal antibody research team and then moving to development in clinical operations, where she managed numerous phase I-III clinical trials with Avonex, Tysabri and Tecfidera in diverse therapeutic areas including, gastroenterology, immunology, neurology, and neuropathic pain.

She continued her career at Merck/EMD Serono where she provided strategic and operational expertise in the planning and conduct of several phase III clinical studies with Rebif and Mavenclad, and with Bavencio, which was approved in merkel cell and urothelial carcinoma.  Later she served as a Chief of Staff to senior leadership.

After almost 20 years in big pharma, Leticia continued her career at various biotech companies: first at Kiniksa Pharmaceuticals, where she was responsible for various programs with high complexity in rare diseases, followed by Black Diamond Therapeutics, working on novel precision oncology therapies for patients with genetically defined cancers. Following that, Leticia provided consultancy services for Nimbus Therapeutics, before joining Brainstorm Cell Therapeutics.

Leticia serves as an IRB Member at Yale University, sits on the Advisory Board of Leal Health, an AI-powered decision-making support platform dedicated to expediting patient access to all available advanced cancer treatments, and is the Chair and President of the New England Chapter of the Association of Clinical Research Professionals (ACRP).

Leticia earned her bachelor’s degree in Biomedical Laboratory and Clinical Sciences from the School of Medicine at Boston University, followed by a master’s degree in Regulatory Affairs and Health Policy from the Massachusetts College of Pharmacy and Health Sciences in Boston.